Market Research Logo

MEDITE Cancer Diagnostics Inc (MDIT) - Financial and Strategic SWOT Analysis Review

MEDITE Cancer Diagnostics Inc (MDIT) - Financial and Strategic SWOT Analysis Review

- provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

  • Business description – A detailed description of the company’s operations and business divisions.
  • Corporate strategy – Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history – Progression of key events associated with the company.
  • Major products and services – A list of major products, services and brands of the company.
  • Key competitors – A list of key competitors to the company.
  • Key employees – A list of the key executives of the company.
  • Executive biographies – A brief summary of the executives’ employment history.
  • Key operational heads – A list of personnel heading key departments/functions.
  • Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
  • Key manufacturing facilities – A list of key manufacturing facilities of the company.
  • Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights

MEDITE Cancer Diagnostics Inc (MEDITE), formerly CytoCore, Inc., specializes in the development, engineering, manufacturing and marketing of premium medical devices and consumables for detection, risk assessment and diagnosis of cancer and related diseases. Its major devices include ultrasonic decalcification instruments, tissue processing instruments, freezing microtome, cryostats, linear staining systems, staining systems, and cytology screening systems. The company’s products find application in processing tissue, cell collection ranging from processing to diagnosis. These devices and consumables are manufactured at is facility in Burgdorf, Germany. The company sells its products through a direct sale force located in Germany, Poland and the US, and also through independent distributors. MEDITE is headquartered in Orlando, Florida, the US.

MEDITE Cancer Diagnostics Inc Key Recent Developments

Nov 15,2017: MEDITE Cancer Diagnostics Appoints Joel Kanter To Its Board As An Independent Director
Nov 08,2017: MEDITE Cancer Diagnostics Reports Appointments of New Chairman of the Board and Chief Executive Officer
Aug 14,2017: MEDITE Cancer Diagnostics Reports 2017 Second Quarter and First Six Month Financial Results
Jul 27,2017: MEDITE Cancer Diagnostics to Launch SureCyte C1 Stain Globally at the 29th European Congress of Pathology
May 10,2017: MEDITE Cancer Diagnostics Announces Reorganization of Germany Operations

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company


Section 1 - About the Company
MEDITE Cancer Diagnostics Inc - Key Facts
MEDITE Cancer Diagnostics Inc - Key Employees
MEDITE Cancer Diagnostics Inc - Key Employee Biographies
MEDITE Cancer Diagnostics Inc - Major Products and Services
MEDITE Cancer Diagnostics Inc - History
MEDITE Cancer Diagnostics Inc - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Section 2 – Company Analysis
Company Overview
MEDITE Cancer Diagnostics Inc - Business Description
MEDITE Cancer Diagnostics Inc - SWOT Analysis
SWOT Analysis - Overview
MEDITE Cancer Diagnostics Inc - Strengths
MEDITE Cancer Diagnostics Inc - Weaknesses
MEDITE Cancer Diagnostics Inc - Opportunities
MEDITE Cancer Diagnostics Inc - Threats
MEDITE Cancer Diagnostics Inc - Key Competitors
Section 3 – Company Financial Ratios
Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts
Section 4 – Company’s Lifesciences Financial Deals and Alliances
MEDITE Cancer Diagnostics Inc, Medical Equipment, Deals By Year, 2012 to YTD 2018
MEDITE Cancer Diagnostics Inc, Medical Equipment, Deals By Type, 2012 to YTD 2018
MEDITE Cancer Diagnostics Inc, Recent Deals Summary
Section 5 – Company’s Recent Developments
Nov 15, 2017: MEDITE Cancer Diagnostics Appoints Joel Kanter To Its Board As An Independent Director
Nov 08, 2017: MEDITE Cancer Diagnostics Reports Appointments of New Chairman of the Board and Chief Executive Officer
Aug 14, 2017: MEDITE Cancer Diagnostics Reports 2017 Second Quarter and First Six Month Financial Results
Jul 27, 2017: MEDITE Cancer Diagnostics to Launch SureCyte C1 Stain Globally at the 29th European Congress of Pathology
May 10, 2017: MEDITE Cancer Diagnostics Announces Reorganization of Germany Operations
Apr 28, 2017: MEDITE Cancer Diagnostics Announces Reorganization of Germany Operations
Apr 27, 2017: MEDITE Cancer Diagnostics Appoints Susan Weisman as Chief Financial Officer
Mar 07, 2017: MEDITE Cancer Diagnostics Appoints Eric M. Goehausen to Board of Directors
Section 6 – Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer
List of Tables
MEDITE Cancer Diagnostics Inc, Key Facts
MEDITE Cancer Diagnostics Inc, Key Employees
MEDITE Cancer Diagnostics Inc, Key Employee Biographies
MEDITE Cancer Diagnostics Inc, Major Products and Services
MEDITE Cancer Diagnostics Inc, History
MEDITE Cancer Diagnostics Inc, Subsidiaries
MEDITE Cancer Diagnostics Inc, Key Competitors
MEDITE Cancer Diagnostics Inc, Ratios based on current share price
MEDITE Cancer Diagnostics Inc, Annual Ratios
MEDITE Cancer Diagnostics Inc, Annual Ratios (Cont...1)
MEDITE Cancer Diagnostics Inc, Annual Ratios (Cont...2)
MEDITE Cancer Diagnostics Inc, Interim Ratios
MEDITE Cancer Diagnostics Inc, Medical Equipment, Deals By Year, 2012 to YTD 2018
MEDITE Cancer Diagnostics Inc, Medical Equipment, Deals By Type, 2012 to YTD 2018
MEDITE Cancer Diagnostics Inc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios
List of Figures
MEDITE Cancer Diagnostics Inc, Performance Chart (2013 - 2017)
MEDITE Cancer Diagnostics Inc, Ratio Charts
MEDITE Cancer Diagnostics Inc, Medical Equipment, Deals By Year, 2012 to YTD 2018
MEDITE Cancer Diagnostics Inc, Medical Equipment, Deals by Type, 2012 to YTD 2018

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report